Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen

Philip Lazarus, Andrea S. Blevins-Primeau, Yan Zheng, Dongxiao Sun

Research output: Chapter in Book/Report/Conference proceedingConference contribution

38 Citations (Scopus)

Abstract

Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor-positive (ER +) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30-50% reduction in both the rate of disease recurrence after 10 years of patient follow-up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM-induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.

Original languageEnglish (US)
Title of host publicationSteroid Enzymes and Cancer
PublisherBlackwell Publishing Inc.
Pages99-111
Number of pages13
ISBN (Print)9781573317450
DOIs
StatePublished - Jan 1 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1155
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Fingerprint

Oncology
Pharmacogenetics
Tamoxifen
Neoplasms
Breast Neoplasms
Therapeutics
Hot Flashes
Selective Estrogen Receptor Modulators
Glucuronosyltransferase
Breast Cancer
Cancer
Enzymes
Endometrial Neoplasms
Metabolites
Venous Thrombosis
Estrogen Receptors
Recurrence
Mortality
Estrogen
Incidence

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Lazarus, P., Blevins-Primeau, A. S., Zheng, Y., & Sun, D. (2009). Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. In Steroid Enzymes and Cancer (pp. 99-111). (Annals of the New York Academy of Sciences; Vol. 1155). Blackwell Publishing Inc.. https://doi.org/10.1111/j.1749-6632.2009.04114.x
Lazarus, Philip ; Blevins-Primeau, Andrea S. ; Zheng, Yan ; Sun, Dongxiao. / Potential role of UGT pharmacogenetics in cancer treatment and prevention : Focus on tamoxifen. Steroid Enzymes and Cancer. Blackwell Publishing Inc., 2009. pp. 99-111 (Annals of the New York Academy of Sciences).
@inproceedings{0991e9ba40964b808a42417fa330c358,
title = "Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen",
abstract = "Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor-positive (ER +) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30-50{\%} reduction in both the rate of disease recurrence after 10 years of patient follow-up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM-induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.",
author = "Philip Lazarus and Blevins-Primeau, {Andrea S.} and Yan Zheng and Dongxiao Sun",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/j.1749-6632.2009.04114.x",
language = "English (US)",
isbn = "9781573317450",
series = "Annals of the New York Academy of Sciences",
publisher = "Blackwell Publishing Inc.",
pages = "99--111",
booktitle = "Steroid Enzymes and Cancer",

}

Lazarus, P, Blevins-Primeau, AS, Zheng, Y & Sun, D 2009, Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. in Steroid Enzymes and Cancer. Annals of the New York Academy of Sciences, vol. 1155, Blackwell Publishing Inc., pp. 99-111. https://doi.org/10.1111/j.1749-6632.2009.04114.x

Potential role of UGT pharmacogenetics in cancer treatment and prevention : Focus on tamoxifen. / Lazarus, Philip; Blevins-Primeau, Andrea S.; Zheng, Yan; Sun, Dongxiao.

Steroid Enzymes and Cancer. Blackwell Publishing Inc., 2009. p. 99-111 (Annals of the New York Academy of Sciences; Vol. 1155).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Potential role of UGT pharmacogenetics in cancer treatment and prevention

T2 - Focus on tamoxifen

AU - Lazarus, Philip

AU - Blevins-Primeau, Andrea S.

AU - Zheng, Yan

AU - Sun, Dongxiao

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor-positive (ER +) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30-50% reduction in both the rate of disease recurrence after 10 years of patient follow-up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM-induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.

AB - Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor-positive (ER +) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30-50% reduction in both the rate of disease recurrence after 10 years of patient follow-up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM-induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.

UR - http://www.scopus.com/inward/record.url?scp=61649101234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649101234&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04114.x

DO - 10.1111/j.1749-6632.2009.04114.x

M3 - Conference contribution

C2 - 19250197

AN - SCOPUS:61649101234

SN - 9781573317450

T3 - Annals of the New York Academy of Sciences

SP - 99

EP - 111

BT - Steroid Enzymes and Cancer

PB - Blackwell Publishing Inc.

ER -

Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. In Steroid Enzymes and Cancer. Blackwell Publishing Inc. 2009. p. 99-111. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.04114.x